Severe sepsis, coagulation, and fibrinolysis: Dead end or one way?

被引：102

作者：

Fourrier, Francois ^{[1
]}

机构：

[1] Univ Lille 2, CHRU Lille, Dept Univ Reanimat, Serv Reanimat Polyvalente,Hop Roger Salengro, F-59800 Lille, France

来源：

CRITICAL CARE MEDICINE | 2012年 / 40卷 / 09期

关键词：

activated protein C; antithrombin; disseminated intravascular coagulation; fibrinolysis; innate immunity; natural anticoagulants; severe sepsis; DISSEMINATED INTRAVASCULAR COAGULATION; RANDOMIZED CONTROLLED-TRIAL; ACTIVATED PROTEIN-C; MULTIPLE ORGAN FAILURE; ANTITHROMBIN-III; PLASMINOGEN-ACTIVATOR; TISSUE FACTOR; SEPTIC SHOCK; HOST-DEFENSE; LUNG INJURY;

D O I：

10.1097/CCM.0b013e318258ff30

中图分类号：

R4 [临床医学];

学科分类号：

100218 [急诊医学];

摘要：

It was suggested more than 30 yrs ago that inhibition of the clotting cascade by natural anticoagulants could decrease the high mortality observed in patients suffering from severe sepsis and septic shock. Unfortunately, this therapeutic "paradigm" has led to a dead end, illustrated by the failure of all randomized trials and the recent withdrawal of recombinant activated protein C. Should we now definitely give up trying to treat septic coagulation disturbances or is there any therapeutic alternative? (Crit Care Med 2012; 40:2704-2708)

引用

收藏

页码：2704 / 2708

页数：5

相关论文

共 38 条

[1]

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].

Abraham, E ;

Reinhart, K ;

Opal, S ;

Demeyer, I ;

Doig, C ;

Rodriguez, AL ;

Beale, R ;

Svoboda, P ;

Laterre, PF ;

Simon, S ;

Light, B ;

Spapen, H ;

Stone, J ;

Seibert, A ;

Peckelsen, C ;

De Deyne, C ;

Postier, R ;

Pettilä, V ;

Sprung, CL ;

Artigas, A ;

Percell, SR ;

Shu, V ;

Zwingelstein, C ;

Tobias, J ;

Poole, L ;

Stolzenbach, JC ;

Creasey, AA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247

[2]

An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation [J].

Asakura, H ;

Ontachi, Y ;

Mizutani, T ;

Kato, M ;

Saito, M ;

Kumabashiri, I ;

Morishita, E ;

Yamazaki, M ;

Aoshima, K ;

Nakao, S .

CRITICAL CARE MEDICINE, 2001, 29 (06) :1164-1168

[3]

Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation [J].

Asakura, H ;

Ontachi, Y ;

Mizutani, T ;

Kato, M ;

Ito, T ;

Saito, M ;

Morishita, E ;

Yamazaki, M ;

Aoshima, K ;

Takami, A ;

Yoshida, T ;

Suga, Y ;

Miyamoto, K ;

Nakao, S .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 67 (03) :170-175

[4]

Fibrinolysis and host response in bacterial infections [J].

Bergmann, Simone ;

Hammerschmidt, Sven .

THROMBOSIS AND HAEMOSTASIS, 2007, 98 (03) :512-520

[5]

Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[6]

From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism? [J].

Borissoff, J. I. ;

Ten Cate, H. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (09) :1791-1794

[7]

Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats [J].

Choi, Goda ;

Hofstra, Jorrit-Jan H. ;

Roelofs, Joris J. T. H. ;

Florquin, Sandrine ;

Bresser, Paul ;

Levi, Marcel ;

van der Poll, Tom ;

Schultz, Marcus J. .

CRITICAL CARE MEDICINE, 2007, 35 (05) :1362-1368

[8]

Tissue Factor, Blood Coagulation, and Beyond: An Overview [J].

Chu, Arthur J. .

INTERNATIONAL JOURNAL OF INFLAMMATION, 2011, 2011

[9]

Activation of protein C following infusion of protein C concentrate in children with severe meningococcal. sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study [J].

de Kleijn, ED ;

de Groot, R ;

Hack, CE ;

Mulder, PGH ;

Engl, W ;

Moritz, B ;

Joosten, KFM ;

Hazelzet, JA .

CRITICAL CARE MEDICINE, 2003, 31 (06) :1839-1847

[10]

Fibrin and fibrinolysis in infection and host defense [J].

Degen, J. L. ;

Bugge, T. H. ;

Goguen, J. D. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 :24-31

← 1 2 3 4 →